New study shows that the amount of active drug in cancer tablets may be reduced by 75% using the Dispersome® technology
Will make it possible to ease patients’ life by reduced tablet burden and lower the environmental impact from toxic drug waste.January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome® technology for reducing the amount of drug in tablet formulations. The Dispersome® technology is a leading drug solubility enhancing technology for tablet formulations, resulting in improved bioavailability. ZERION believes that this technology can be